Oil supplementation with a special combination of n-3 and n-6 long-chain polyunsaturated fatty acids does not protect for exercise induced asthma: a double-blind placebo-controlled trial

Lipids in Health and Disease

N. Benker¹  D. Fussbroich¹  R. Schubert¹  L. Böhler¹  S. Zielen¹  J. Schulze¹  M. Dreßler¹  C. Beermann²  M. Tytyk²  E. Herrmann³ 

[1] Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic fibrosis, Goethe-University;Department of Food Technology, University of Applied Science;Institute of Biostatistics and Mathematical Modelling, Goethe-University;

关键词: Exercise-induced asthma;    Exercise challenge;    Forced expiratory volume in 1 s;    Exhaled nitric oxide;    Long-chain polyunsaturated fatty acids;    Double-blind placebo-controlled trial;   

DOI  :  10.1186/s12944-020-01343-2

来源: DOAJ

【 摘 要 】

Abstract Background Many patients suffering from exercise-induced asthma (EIA) have normal lung function at rest and show symptoms and a decline in FEV1 when they do sports or during exercise-challenge. It has been described that long-chain polyunsaturated fatty acids (LCPUFA) could exert a protective effect on EIA. Methods In this study the protective effect of supplementation with a special combination of n-3 and n-6 LCPUFA (sc-LCPUFA) (total 1.19 g/ day) were investigated in an EIA cold air provocation model. Primary outcome measure: Decrease in FEV1 after exercise challenge and secondary outcome measure: anti-inflammatory effects monitored by exhaled NO (eNO) before and after sc-LCPUFA supplementation versus placebo. Results Ninety-nine patients with exercise-induced symptoms aged 10 to 45 were screened by a standardized exercise challenge in a cold air chamber at 4 °C. Seventy-three patients fulfilled the inclusion criteria of a FEV1 decrease > 15% and were treated double-blind placebo-controlled for 4 weeks either with sc-LCPUFA or placebo. Thirty-two patients in each group completed the study. Mean FEV1 decrease after cold air exercise challenge and eNO were unchanged after 4 weeks sc-LCPUFA supplementation. Conclusion Supplementation with sc-LCPUFA at a dose of 1.19 g/d did not have any broncho-protective and anti-inflammatory effects on EIA. Trial registration Clinical trial registration number: NCT02410096. Registered 7 February 2015 at Clinicaltrial.gov

【 授权许可】

Unknown